FDA Approves Cavhanza Nilotinib ODT

Key Takeaways

• Cavhanza is approved for newly diagnosed adult Ph+ CML in chronic phase and for adults with chronic or accelerated phase disease resistant or intolerant to prior therapy including imatinib.
• Recommended dosing cited after approval is 120 mg twice daily for newly diagnosed chronic-phase adults and 160 mg twice daily for resistant or intolerant chronic/accelerated-phase adults.
• Cycle says the ODT maintains bioavailability with PPIs or H2 antagonists and showed no food effect in clinical trials.
• Cavhanza is not interchangeable milligram-for-milligram with other nilotinib products.

What did the FDA approve on June 2, 2026?

Cycle Pharmaceuticals announced FDA approval of Cavhanza (nilotinib) orally disintegrating tablets in a June 2, 2026 Business Wire release. The product is a BCR-ABL tyrosine kinase inhibitor formulation for Ph+ CML adults.

Indications cover newly diagnosed Ph+ CML in chronic phase and adults with chronic or accelerated phase Ph+ CML who are resistant or intolerant to prior therapy that included imatinib. Cycle described an upcoming commercial launch at the time of the announcement and framed Cavhanza as its second CML-supportive portfolio entry.

How is Cavhanza dosing different from other nilotinib products?

Reports on the approval describe 60 mg and 80 mg ODT strengths. Newly diagnosed chronic-phase adults are directed to 120 mg twice daily. Resistant or intolerant chronic- or accelerated-phase adults are directed to 160 mg twice daily.

Prescribers must treat Cavhanza as non-substitutable with other nilotinib products on a milligram-per-milligram basis. Automatic pharmacy substitution could underdose or overdose patients if older strength paradigms are applied without a new prescription.

Why do acid-reducing agents matter for nilotinib?

Cycle states that about 25% of Ph+ CML patients are co-prescribed proton pump inhibitors or H2 antagonists. Those agents can compromise exposure for conventional nilotinib when food and acid constraints are binding in daily practice.

Cavhanza is positioned to keep bioavailability more stable without PPI or H2 timing workarounds. Company materials also report no food effect, supporting dosing without regard to meals and administration with or without water for patients who struggle to swallow conventional tablets.

Where does this sit versus earlier nilotinib evidence?

Nilotinib’s role in CML rests on earlier randomized evidence such as ENESTnd versus imatinib in newly diagnosed chronic-phase disease. Peer-reviewed discussion of that landscape is available via PMC4800682.

Cavhanza is a formulation change, not a new molecular entity. Differentiation will depend on adherence, acid-reducer co-prescribing patterns, and careful switch management rather than a novel kinase target.

Historical FDA labeling for nilotinib products, including pediatric chronic-phase updates summarized on FDA.gov, shows how the molecule’s indications evolved before this ODT arrived.

What should pharmacy and medical affairs teams check?

Add non-interchangeability alerts to formularies and e-prescribing catalogs. Retrain clinicians and pharmacists that twice-daily totals and tablet strengths differ from other nilotinib brands.

Counseling scripts should cover PPI and H2 co-medication under the new label, swallowing instructions for ODTs, and the usual nilotinib class monitoring for metabolic and cardiovascular adverse effects known to the TKI class.

• Verify NDC and strength before automatic substitution.
• Document indication: new diagnosis versus resistant or intolerant disease.
• Reconcile home acid-reducer lists at each visit.

What remains unproven?

Public materials around the approval emphasize convenience and exposure flexibility. They do not establish head-to-head superiority on major molecular response rates versus older nilotinib tablets solely because of the ODT platform.

Whether real-world adherence improves in PPI-using cohorts still needs post-launch observational data. Until then, treat Cavhanza as a formulation option inside an established TKI class rather than a new efficacy paradigm.

Commercial teams should also watch how payers classify Cavhanza relative to other nilotinib SKUs. If medical policies still list older brand strengths only, claims edits may reject the ODT NDC until policies are updated. Specialty pharmacies need explicit counseling scripts so patients do not split or combine tablets to mimic prior milligram totals.

From a competitive standpoint, Cavhanza enters a mature BCR-ABL market where adherence friction and acid-reducer co-prescribing are practical differentiators. Cycle’s claim set is therefore operational rather than mechanistic: keep exposure stable when meals and PPIs complicate older regimens. That is a legitimate medical-affairs narrative if it stays tethered to the approved label.

Related NovaPharma coverage

• FDA approves oral nilotinib tablets for Ph+ CML
• FDA approves Bosulif for pediatric CML
• Outlook Therapeutics LYTENAVA FDA resubmission

Frequently Asked Questions

Primary Sources

1. Business Wire: Cavhanza FDA approval
2. PMC: nilotinib CML clinical context
3. FDA: nilotinib CML approval resources